scholarly journals Effect of selenium as an adjunctive therapy in patients with treatment-resistant obsessive-compulsive disorder: A pilot randomized double blind placebo-controlled clinical trial

2018 ◽  
Vol 20 (4) ◽  
pp. 57-65 ◽  
Author(s):  
mehdi Sayyah ◽  
Mina Andishmand ◽  
Reza Ganji
Keyword(s):  
Clinical Trial ◽  
Obsessive Compulsive Disorder ◽  
Adjunctive Therapy ◽  
Controlled Clinical Trial ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Compulsive Disorder

Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial

CNS Spectrums ◽  
2019 ◽  
Vol 25 (4) ◽  
pp. 552-556
Author(s):  
Arash Mowla ◽  
Mehrnoosh Ghaedsharaf
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Obsessive Compulsive Disorder ◽  
Controlled Clinical Trial ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Good Tolerability ◽  
Double Blind Placebo ◽  
Compulsive Disorder ◽  
Current Medication

AbstractBackground and objective.Glutamate dysfunction has been shown to be associated with pathophysiology of obsessive–compulsive disorder (OCD). Our objective is to survey the effects of pregabalin (a glutamate-modulating agent) as an augmenting treatment for resistant OCD.Patients and methods.In this 12-week double-blind placebo-controlled clinical trial, 56 patients with resistant OCD were randomly allocated to receive either pregabalin or placebo plus their current medication (sertraline). Yale–Brown Obsessive Compulsive Scale (Y-BOCS) was used to evaluate the outcomes. Adverse effects were also registered.Results.Of the 56 patients with resistant OCD who were randomly allocated in 2 groups of pregabalin (n = 28) and placebo group (n = 28), 42 patients (22 in pregabalin group and 20 in placebo group) completed the trial. Throughout the trial, the mean score decreased from 26.13± 7.03 to 8.81 ± 3.47 in the pregabalin group (p < 0) and from 26.85 ± 4.34 to 17.63 ± 4.22 in the placebo group (p < 0). At the end of trial, 16 (57.14%) patients in the pregabalin group and 2 (7.14%) patients in the placebo group showed more than 35% decline in YBOCS (p < .01). The pregabalin group showed good tolerability and safety.Conclusions.Our study revealed that pregabalin, as an augmenting medication, is more effective than placebo in the treatment of patients with resistant OCD.

Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder

2017 ◽  
Vol 78 (7) ◽  
pp. e766-e773 ◽  
Author(s):  
Daniel L. C. Costa ◽  
Juliana B. Diniz ◽  
Guaraci Requena ◽  
Marinês A. Joaquim ◽  
Christopher Pittenger ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Controlled Trial ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Compulsive Disorder

Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

2010 ◽  
Vol 72 (05) ◽  
pp. 716-721 ◽  
Author(s):  
Heather A. Berlin ◽  
Lorrin M. Koran ◽  
Michael A. Jenike ◽  
Nathan A. Shapira ◽  
William Chaplin ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Controlled Trial ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Compulsive Disorder

scholarly journals Granisetron Augmentation of Sertraline in Obsessive-Compulsive Disorder: A Double-Blind Placebo-Controlled, Randomized Clinical Trial

2022 ◽  
Author(s):  
Ala Ghobadian ◽  
Saba Mokhtari ◽  
Behnam Shariati ◽  
Leila Kamalzadeh ◽  
Mohsen Shati ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Obsessive Compulsive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Complete Response ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder

Abstract Background: Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20–30%, and satisfactory treatment is obtained in 40–60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the patients’ function. Therefore, it is necessary to investigate possible strategies to improve the mitigation of symptoms.In this study, the main objective was to examine and investigate the effectiveness of granisetron, which is a serotonin 5-hydroxytryptamine receptor type 3 (5-HT3) antagonist, as an adjunct therapy to selective serotonin reuptake inhibitors, for the purpose of ameliorating OCD symptoms. Methods: fifty-eight patients diagnosed with OCD, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, who had a Yale-Brown obsessive-compulsive scale (Y-BOCS) score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either granisetron (1 mg twice daily) and sertraline (100 mg daily initially followed by 200 mg daily after week 4) or placebo and sertraline. The primary outcome was OCD symptoms measured by the Y-BOCS.Results: Y-BOCS total score significantly dropped in both groups (28.9 to 17.7 for granisetron and 27.5 to 19.3 for placebo group with a slightly greater drop for granisetron group), while the granisetron group experienced a significantly greater reduction in obsession scores (Greenhouse-Geisser F(2.32,97.57)=4.52,p-value=0.01). Moreover, in comparison with the placebo group, the proportion of the patients showing complete response was considerably higher among the granisetron group (P-value <0.01). No major adverse effects were observed in any of the groups. Conclusion: The results suggest that granisetron augmentation of sertraline may increase the rate of response in patients with moderate to severe non-refractory OCD. Further studies are suggested in this regard.Trial registration: The trial was registered at the Iranian Registry of Clinical Trials on 27/03/2019 (www.irct.ir; IRCT ID: IRCT20170123032145N3).

EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)

2012 ◽  
Vol 29 (10) ◽  
pp. 850-854 ◽  
Author(s):  
Mehdi Sayyah ◽  
Mohammad Sayyah ◽  
Hatam Boostani ◽  
Seyyed Mohammad Ghaffari ◽  
Abedin Hoseini
Keyword(s):  
Clinical Trial ◽  
Obsessive Compulsive Disorder ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Double Blind Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document